Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide....